Data / Drug companies / Olmesartan medoxomil
Olmesartan medoxomil: 31 companies and 129 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Olmesartan medoxomil is listed in the FDA National Drug Code Directory by 31 companies, with 129 products in commercial distribution. 123 of the products (95.3%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, film coated; tablet, coated; tablet, and the newest product started marketing on August 7, 2026.
The request: Get every company that lists olmesartan medoxomil in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 31
- Products
- 129
- Generic (ANDA) products
- 123 (95.3%)
- Application numbers
- 16
- Routes
- Oral
- Brand names
- Benicar
- openFDA record search
- api.fda.gov
Companies that list olmesartan medoxomil
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| A-S Medication Solutions | 16 | tablet, film coated; tablet | Generic drugs (ANDA) | March 4, 2022 |
| Bryant Ranch Prepack | 14 | tablet, film coated; tablet, coated | Generic drugs (ANDA) | October 7, 2024 |
| Direct_Rx | 7 | tablet, film coated; tablet | Generic drugs (ANDA) | February 6, 2026 |
| Cosette Pharmaceuticals, Inc. | 6 | tablet, film coated | New drug applications (NDA) | August 1, 2025 |
| Bryant Ranch Prepack | 5 | tablet, film coated | Generic drugs (ANDA) | June 29, 2018 |
| Remedyrepack Inc. | 5 | tablet, film coated; tablet, coated | Generic drugs (ANDA) | March 25, 2026 |
| Proficient Rx LP | 4 | tablet, film coated; tablet, coated | Generic drugs (ANDA) | April 24, 2017 |
| Accord Healthcare Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | February 16, 2018 |
| Alembic Pharmaceuticals Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | April 24, 2017 |
| Alembic Pharmaceuticals Limited | 3 | tablet, film coated | Generic drugs (ANDA) | April 24, 2017 |
| Ascend Laboratories, LLC | 3 | tablet, coated | Generic drugs (ANDA) | April 24, 2017 |
| Aurobindo Pharma Limited | 3 | tablet, film coated | Generic drugs (ANDA) | April 24, 2017 |
| Cadila Pharmaceuticals Limited | 3 | tablet, coated | Generic drugs (ANDA) | January 1, 2025 |
| Camber Pharmaceuticals, Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | May 23, 2025 |
| Chartwell RX, LLC | 3 | tablet | Generic drugs (ANDA) | March 5, 2019 |
| Glenmark Pharmaceuticals Inc., USA | 3 | tablet, film coated | Generic drugs (ANDA) | May 25, 2017 |
| Golden State Medical Supply, Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | June 29, 2018 |
| Hec Pharm USA Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | April 10, 2026 |
| Inventia Healthcare Limited | 3 | tablet, coated | Generic drugs (ANDA) | May 29, 2020 |
| Jubilant Cadista Pharmaceuticals Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | April 1, 2016 |
| Lannett Company, Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | March 5, 2019 |
| Lifestar Pharma LLC | 3 | tablet | Generic drugs (ANDA) | May 1, 2020 |
| Macleods Pharmaceuticals Limited | 3 | tablet | Generic drugs (ANDA) | April 25, 2017 |
| Modavar Pharmaceuticals LLC | 3 | tablet, coated | Generic drugs (ANDA) | July 1, 2025 |
| NorthStar RxLLC | 3 | tablet | Generic drugs (ANDA) | August 7, 2026 |
| Novadoz Pharmaceuticals LLC | 3 | tablet, film coated | Generic drugs (ANDA) | January 18, 2023 |
| Quallent Pharmaceuticals Health LLC | 3 | tablet, film coated | Generic drugs (ANDA) | August 1, 2023 |
| Rising Pharma Holdings, Inc. | 3 | tablet, coated | Generic drugs (ANDA) | October 7, 2024 |
| ScieGen Pharmaceuticals, Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | June 29, 2018 |
| Solco Healthcare US, LLC | 3 | tablet | Generic drugs (ANDA) | March 4, 2022 |
| Umedica Laboratories USA Inc. | 3 | tablet | Generic drugs (ANDA) | February 15, 2026 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 76 | 58.9% |
| Tablet, coated | 27 | 20.9% |
| Tablet | 26 | 20.2% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 123 | 95.3% |
| New drug applications (NDA) | 6 | 4.7% |
Pharmacologic classes
| Class | Products |
|---|---|
| Angiotensin 2 Receptor Blocker | 129 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.